Robert Rosen, MD
Family Medicine · Winston-Salem, NCNPI 1760477335
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $22,507 of the $33,383 with a category attached, or 67.4%. 60 manufacturers reported payments, led by Abbott at 27.3% of the total. Among family medicine clinicians in NC with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,107 payments — averaging $30.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$9K
- AstraZeneca$3K
- Novo Nordisk$3K
- Sanofi-aventis U.S. LLC$3K
- AbbVie$2K
- Pfizer$2K
- plus $11K from 54 others
Across 361 payments — averaging $5297.40 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Bavarian Nordic A/s$920K
- Visby Medical, Inc.$425K
- Seqirus USA Inc$194K
- Regeneron$144K
- Pfizer$67K
- GSK$48K
- plus $114K from 9 others
What the payments were for
- Consulting fees$8,11824%
- Speaking & faculty fees$2,1136%
- Travel & lodging$6272%
- Food & beverage$22,50767%
- Education$190%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FREESTYLE LIBRE 3$8,531
- SOLIQUA 100/33$2,403
- FARXIGA$1,068
- QULIPTA$459
- UBRELVY$355
- Wegovy$354
- Ozempic$349
- AIRSUPRA$311
- Phasix Mesh$280
- MOUNJARO$150
- FUROSCIX$125
- BREZTRI$125
- DEXCOM G6 TRANSMITTER$125
- DEXCOM G7 GSS (161)$124
- XARELTO$120
- AIMOVIG$111
- EVENITY$106
- INVOKANA$105
- Leqembi$103
- ZAVZPRET$102
How this compares
$33,383 in reported general payments places this provider in the 95th percentile of 3,444 family medicine providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 107 | $120,573 |
| RybelsusSemaglutide | 72 | $102,133 |
| FarxigaDapagliflozin Propanediol | 123 | $100,968 |
| EliquisApixaban | 139 | $97,015 |
| XareltoRivaroxaban | 78 | $79,923 |
| Tresiba Flextouch U-200Insulin Degludec | 20 | $47,770 |
| JardianceEmpagliflozin | 46 | $42,615 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 36 | $41,078 |
| TrulicityDulaglutide | 41 | $39,640 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 31 | $35,267 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 37 | $30,775 |
| ArexvyRsvpref3 Antigen/As01e/Pf | 85 | $26,263 |
| MyrbetriqMirabegron | 30 | $25,758 |
| Breo ElliptaFluticasone/Vilanterol | 35 | $18,336 |
| JanuviaSitagliptin Phosphate | 12 | $18,281 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $3,168 | $222,706179 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Brilinta | $3,331 | $115,807150 claims |
| GSKTrelegy Ellipta, Arexvy, Breo Ellipta, Anoro Ellipta, Shingrix | $809 | $98,449218 claims |
| PfizerEliquis | $1,819 | $97,015139 claims |
| Johnson & JohnsonXarelto | $844 | $79,92378 claims |
| Boehringer IngelheimJardiance, Spiriva Respimat | $517 | $50,55861 claims |
| Lilly USA, LLCTrulicity, Humalog | $1,452 | $41,83152 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $3,055 | $41,07836 claims |
| Astellas Pharma US IncMyrbetriq | $391 | $25,75830 claims |
| MerckJanuvia | $263 | $18,28112 claims |
| NovartisEntresto | $338 | $15,78914 claims |
| AbbVieLinzess | $2,019 | $8,17215 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,444 family medicine providers in North Carolina.
Other family medicine in Winston-Salem
- William CromwellRaleigh$879K
- Steve VacalisGastonia$693K
- David DundeeWinston Salem$633K
- Kevin SodenCharlotte$558K
- Brian ForrestApex$398K
- Joseph KonenCharlotte$322K
- Richard RachimaCharlotte$294K
- Dimitrios HondrosCharlotte$275K
- Domingo Rodriguez-CueGarner$253K
- Christopher ChaoCary$201K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.